This application relates to a use of IL-l.beta. ；-ligand/IL-l receptordisrupting compounds (herein referred to as "IL-lbeta Compounds") ； such assmall molecular compounds disrupting IL-l.beta.； ligand - IL-I receptorinteraction, IL-l.beta.； antibodies or IL-I receptor antibodies, e.g. IL-l.beta.； binding molecules described herein, e.g. antibodies disclosed herein,e.g. IL-l.beta.； binding compounds or IL-I receptor binding compounds, and/orRNA compounds decreasing either IL-l.beta.； ligands or IL-I receptor proteinlevels, in the treatment and/or prevention of auto-inflammatory syndromes,e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome andto methods of treating and/or preventing auto-inflammatory syndromes, e.g.Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, inmammals, particularly humans .
